* GeoVax Labs Inc reported a quarterly adjusted loss of 91 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-4.80. The mean expectation of four analysts for the quarter was for a loss of $1.48 per share. Wall Street expected results to range from $-2.04 to -91 cents per share.
* Revenue was $2.79 million; analysts expected $918.75 thousand.
* GeoVax Labs Inc's reported EPS for the quarter was a loss of 91 cents.
* The company reported a quarterly loss of $5.82 million.
* GeoVax Labs Inc shares had risen by 30.3% this quarter and lost 42.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 3.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for GeoVax Labs Inc is 16.50 This summary was machine generated from LSEG data November 12 at 11:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.48 -0.91 Beat
Jun. 30 2024 -3.36 -1.99 Beat
Mar. 31 2024 -5.56 -2.47 Beat
Dec. 31 2023 -2.78 -13.60 Missed
Comments